Skip to main content

Table 4 Known groups validity testing: Comparison of QLQ-BN20 Scores as a function of KPS and MMSE

From: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran

   KPS Effect size MMSE** Effect size
   >80 ≤80 <27 ≥27
Baseline N = 53, N = 141, N = 91 N = 103
Follow-up N = 41 N = 153
BFU (future uncertainty) Baseline*‡ 42.7 (22.2) 33.5 (24.7) 0.38 33.9 (24.4) 27.2 (23.4) 0.28
Follow-up * 37.0 (15.1) 25.6 (24.5) 0.50 - - -
BVD (visual disorder) Baseline *‡ 38.3 (30.1) 27.0 (27.3) 0.40 28.1 (29.4) 21.8 (22.8) 0.24
Follow-up * 33.3 (27.8) 23.7 (26.1) 0.36 - -  
BMD (motor dysfunction) Baseline*‡ 68.2 (31.8) 24.6 (26.3) 1.56 33.7 (30.2) 16.5 (22.5) 0.65
Follow-up * 63.9 (29.1) 22.4 (27.0) 1.5 - -  
BCD (communication deficit) Baseline *‡ 44.9 (31.9) 20.3 (26.5) 0.88 26.1 (28.3) 14.1 (21.8) 0.48
Follow-up* 45.0 (33.4) 17.0 (22.6) 1.11 - -  
BHA (headaches) Baseline *‡ 50.0 (36.0) 44.3 (32.2) 0.17 47.8 (28.6) 34.8 (34.4) 0.41
Follow-up * 63.3 (36.7) 42.5 (35.1) 0.59 - -  
BSE (seizures) Baseline *‡ 15.1 (22.9) 11.0 (23.3) 0.18 14.3 (25.5) 5.7 (15.6) 0.41
Follow-up * 14.8 (24.2) 8.5 (21.2) 0.29 - -  
BDR (drowsiness) Baseline *‡ 57.6 (30.1) 28.3 (31.2) 0.95 34.7 (33.3) 22.3 (25.0) 0.42
Follow-up * 66.7 (27.2) 26.6 (30.5) 1.34 - -  
BHL (hair loss) Baseline*‡ 33.3 (35.1) 22.1 (32.2) 0.34 23.4 (32.8) 16.8 (33.5) 0.20
Follow-up* 63.3 (36.7) 42.5 (35.1) 0.59 - -  
BIS (itchy skin) Baseline*‡ 33.3 (35.1) 13.2 (24.7) 0.72 19.2 (30.4) 9.2 (17.6) 0.41
Follow-up* 40.0 (37.8) 16.5 (26.5) 0.80 - -  
BBC (bladder control) Baseline*‡ 45.4 (37.3) 12.8 (24.2) 1.15 19.0 (27.3) 9.2 (23.4) 0.39
  Follow-up* 50.0 (42.3) 12.9 (28.2) 0.97 - -  
  1. * Statistically significant for KPS.
  2. ‡ Statistically significant for MMSE.
  3. ** MMSE was only available at baseline.